Single-cell Omics Market Outlook:
Single-cell Omics Market size was over USD 4.06 billion in 2025 and is projected to reach USD 20.89 billion by 2035, witnessing around 17.8% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of single-cell omics is evaluated at USD 4.71 billion.
A demographic-based prediction from the American Cancer Society calculated the new and death cases of malignancy worldwide to be 20 million in 2022, which is further estimated to reach 35 million by 2050. It also mentioned the count of mortality resulted by this ailment to be and 9.7 million in 2022. Single-cell omics provide a powerful tool to segregate and analyze carcinoma cells individually, helping researchers identify the targets that contribute to tumor development progression and response to therapy. This signifies the importance of this transcription method in extensive clinical research. Thus, the continuous demand for personalized medicine in this category is fueling growth in the single-cell omics market.
On this note, a 2021 NLM study revealed that the advances in functional single-cell omics improved the understanding of intra-patient diversity and biological mechanisms of tumour evolution, prognosis, and drug resistance in cancer. However, the enlarging financial exhaustion on cancer patients has become a serious issue, where ongoing R&D cohorts aim at reducing this burden. According to an article published by the ASCO Publication, the annual spending per patient on related treatments, such as CAR T-cell therapy, was USD 500,000.0 till 2021. Thus, the efforts from both public and private organizations are currently dedicated to decrease the payers’ pricing of these therapeutics to make it more accessible by lowering the cost of analysis per cell for research-associated individuals.
